Nurix Therapeutics NRIX
NASDAQ NRIX
$25.51 -0.51 (-1.96%)
At close: Oct 22, 2026 · 4:00 PM EDT

Nurix Therapeutics (NRIX) EBIT Margin (2019 - 2026)

Updated

Nurix Therapeutics (NRIX) posted EBIT Margin of 83.12% for fiscal Q3 2026 (quarter ended Aug 31, 2026), up 1240.77 percentage points from -1157.65% a year earlier and up 1124.85 percentage points from the prior quarter.

Analysis

Nurix Therapeutics (NRIX) EBIT Margin (2019 - 2026) Analysis & Trends

For the trailing twelve months through Aug 31, 2026, EBIT Margin at Nurix Therapeutics was 41.27%, up 360.58 percentage points year-over-year; for FY2025 (ended Nov 30, 2025), it was -340.16%, up 50.36 percentage points from FY2024.

  • Annual EBIT Margin shows a five-year change of +24.50 percentage points (FY2020 to FY2025).
  • In prior fiscal years, Nurix Therapeutics' EBIT Margin was -390.52% in FY2024 (-189.11 pp), -201.41% in FY2023 (+274.59 pp), -476.01% in FY2022 (-79.75 pp) and -396.26% in FY2021 (-31.59 pp).
  • The fiscal Q3 2026 figure stands as the highest quarterly EBIT Margin in data going back to fiscal Q3 2019.
  • On a year-over-year basis, EBIT Margin increased in two of the last eight quarters, with an average year-over-year change of -205.39 percentage points.
  • The strongest year-over-year quarter for EBIT Margin in the past five years was fiscal Q3 2026, with a gain of 1240.77 percentage points; the weakest was fiscal Q1 2026, with a drop of 1138.78 percentage points.
  • According to Business Quant data, EBIT Margin for the three prior fiscal quarters was -1041.73% (Q2 2026), -1479.45% (Q1 2026) and -612.03% (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn 24.35%
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn 37.86%
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn -3.52%
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn 32.97%
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn 20.57%
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn 34.95%
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -133.21%
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn 28.37%
10 Nurix Therapeutics 2.84 Bn 215.50 Mn - 83.12%
Historic Data

Historic Data

Download Data
DateValue
Aug 31, 2026 83.12%
May 31, 2026 -1,041.73%
Feb 28, 2026 -1,479.45%
Nov 30, 2025 -612.03%
Aug 31, 2025 -1,157.65%
May 31, 2025 -109.68%
Feb 28, 2025 -340.67%
Nov 30, 2024 -486.73%
Aug 31, 2024 -433.83%
May 31, 2024 -401.42%
Feb 29, 2024 -272.65%
Nov 30, 2023 -299.06%
Aug 31, 2023 -216.67%
May 31, 2023 -87.25%
Feb 28, 2023 -338.60%
Nov 30, 2022 -717.82%
Aug 31, 2022 -432.93%
May 31, 2022 -399.89%
Feb 28, 2022 -444.28%
Nov 30, 2021 -513.16%
API Access

Nurix Therapeutics EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=NRIX&period=max&api_key=YOUR_API_KEY